Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Plus Pioglitazone for HFpEF
NCT03794518Phase 3Unknown
- Sponsor
- Hamad Medical Corporation
- Start
- Mar 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Pioglitazone + Dapagliflozin with Placebo (2 arms). Primary endpoint: Time to first hospitalization for heart failure after starting intervention at 3 years. Status: unknown.
02
Drugs
pioglitazonedapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03794518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794518.